Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Open accessThe DOI matches its Crossref record; 148 of the 151 references it cites were found in a registry or an index; 54 of the 207 sources its claims cite were checked for support.
Abstract
Hallucinogens are a loosely defined group of compounds including LSD, N,N-dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and ex vivo, and the various molecular imaging studies with positron emission tomography (PET) or single photon emission computer tomography (SPECT). In general, molecular imaging can depict the uptake and binding distribution of labelled hallucinogenic compounds or their congeners in the brain, as was shown in an early PET study with N1-([11C]-methyl)-2-bromo-LSD ([11C]-MBL); displacement with the non-radioactive competitor ketanserin confirmed that the majority of [11C]-MBL specific binding was to serotonin 5-HT2A receptors. However, interactions at serotonin 5HT1A and other classes of receptors and pleotropic effects on second messenger pathways may contribute to the particular experiential phenomenologies of LSD and other hallucinogenic compounds. Other salient aspects of hallucinogen action include permeability to the blood–brain barrier, the rates of metabolism and elimination, and the formation of active metabolites. Despite the maturation of radiochemistry and molecular imaging in recent years, there has been only a handful of PET or SPECT studies of radiolabeled hallucinogens, most recently using the 5-HT2A/2C agonist N-(2[11CH3O]-methoxybenzyl)-2,5-dimethoxy- 4-bromophenethylamine ([11C]Cimbi-36). In addition to PET studies of target engagement at neuroreceptors and transporters, there is a small number of studies on the effects of hallucinogenic compounds on cerebral perfusion ([15O]-water) or metabolism ([18F]-fluorodeoxyglucose/FDG). There remains considerable scope for basic imaging research on the sites of interaction of hallucinogens and their cerebrometabolic effects; we expect that hybrid imaging with PET in conjunction with functional magnetic resonance imaging (fMRI) should provide especially useful for the next phase of this research.
Overview
CoChat Summary
TL;DR
This is a narrative review of in vitro, ex vivo, PET/SPECT, and perfusion/metabolic imaging studies of hallucinogens, with a particular focus on serotonin receptor pharmacology and brain target engagement. Across the literature summarized, hallucinogens are presented as chiefly 5-HT2A agonists, but with important contributions from other receptors, metabolism, and flow-metabolism coupling to their effects.
Key findings
- The review states that hallucinogens generally share agonism at 5-HT2A sites, but many also show high affinity at 5HT2C and 5HT1A receptors; for example, LSD had Ki values of 3 nM at 5HT1A, 4 nM at 5HT2A, and 15 nM at 5HT2C sites, while psilocin had Ki values of 49 nM at 5HT2A, 94 nM at 5HT2C, and 123 nM at 5HT1A sites.
- In human PET work, psilocybin/psilocin produced substantial 5HT2A occupancy: Madsen et al. reported occupancy as high as 76% at plasma psilocin around 100 nM, and Hasler et al. reported widespread 50% decreases in [18F]-altanserin uptake after 20 mg psilocybin in 11 healthy young male subjects.
- Imaging findings summarized include both increased and decreased cerebral activity depending on tracer and modality: psilocybin increased CMRglc by up to +25% in frontal cortex, anterior cingulate, and medial temporal cortex in one FDG PET study (n = 10), while ASL/SPECT studies often found reduced perfusion in widespread regions after psilocybin or mescaline.
- The review notes that radiolabeled hallucinogen studies are still sparse despite modern radiochemistry; it specifically highlights early [11C]-MBL PET showing cortical binding displaced by ketanserin, and says there remains “considerable scope” for further PET/SPECT and hybrid PET-fMRI research.
Methods
- Narrative review of published literature on hallucinogen binding in vitro and ex vivo, plus molecular imaging studies using PET and SPECT; the article also discusses a smaller number of studies of cerebral perfusion and metabolism.
- Evidence base spans animals and humans, including rats, mice, pigs, baboons, rabbits, monkeys, and healthy volunteers, as well as a clinical Ayahuasca study in patients with recurrent major depressive disorder.
- Main analyses discussed include receptor-binding displacement/affinity studies, autoradiography, PET/SPECT tracer studies, competition paradigms (e.g., [11C]-raclopride, [18F]-altanserin, [11C]-Cimbi-36), and FDG/ASL perfusion imaging.
Limitations
- The paper explicitly states that the molecular imaging literature on hallucinogens is “rather sparse,” with only a handful of PET/SPECT studies and some well-known hallucinogens “entirely uninvestigated” by molecular imaging.
- Several findings are presented as interpretive or tentative, including possible confounding by anesthesia, metabolite effects, or drug mis-injection in animal imaging studies; these caveats are stated in the text.
- By its own framing, this is a narrative review rather than a systematic review or meta-analysis; that limits the ability to draw pooled quantitative conclusions from the evidence presented.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 [11C]-Cimbi-36 (38) activity summed over the 45 min scan time in rat brain (right) overlaid on an MR template image in the horizontal plane (left). High activity in cortical regions, especially mPFC, moderate activity in striatal and hippocampal regions and low binding in cerebellum.](https://figures.cochat.ai/paper-figures/7b9930eac10a40ccaf77b666dc8f4fca/molecular-and-functional-imaging-studies-of-psychedelic-drug-action-in-animals-figure-4.jpg)

![Figure 6 Inverse Correlation of 5D-ASC Global Scale scores and [18F]-altanserin (39) apparent distribution volume [DV’]. Results of a voxel based correlation analysis (Δ 5D-ASC global vs. ΔDV’, threshold p < 0.005, uncorrected) using Statistical Parametric Mapping [105]. Reproduced with permission.](https://figures.cochat.ai/paper-figures/9569a3fbfefc446a971749e9573d99ea/molecular-and-functional-imaging-studies-of-psychedelic-drug-action-in-animals-figure-6.jpg)
![Figure 7 Mean parametric maps of the total distribution volume of 5-[11C]-MeO-DMT (47) in brain of groups of three pigs at baseline and after treatment with the irreversible MAO A/B inhibitor, pargyline. There was no evidence of potentiation of the tracer uptake by blockade of MAO, nor was the binding in ventral striatum displaceable in studies with ketanserin (7) pretreatment (Jensen and Cumming, unpublished observations).](https://figures.cochat.ai/paper-figures/6893b4bed847409db7773772b99ee74d/molecular-and-functional-imaging-studies-of-psychedelic-drug-action-in-animals-figure-7.jpg)
Verification
Claims the paper makes
47 Valid · 5 Not valid · 140 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A prohibition against hallucinogen research established in many countries the 1970s was until recently an impediment to progress in our understanding of the phenomenology and physiology of hallucinogen action [2,3];”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 1. Introduction Structurally diverse ergolines, phenylethylamines, and tryptamines known collectively as hallucinogens induce perceptual and affective changes, extending from sensory distortions (illusions) to sensing of non-existent objects (hallucinations), with varying degree of control over or insight into the altered state. The sites of hallucinogen binding and action in the central nervous system are amenable to study by molecular imaging with positron emission tomography (PET) or single photon emission computer tomography (SPECT), and can now be studied by functional magnetic resonance imaging (fMRI) of cerebral perfusion and connectivity [1]. A prohibition against hallucinogen research established in many countries the 1970s was until recently an impediment to progress in our understanding of the phenomenology and physiology of hallucinogen action [2,3]; PubMed hits for the search term “hallucinogen” peaked in 1974, troughed around 1990, and have sustained a high level since 2010. Analysis of the literature in the past decade shows a shift in emphasis from preclinical studies especially of lysergic acid diethylamide (LSD) (1) towards more clinical applications, especially involving psilocybin (2) [4]. Indeed, there is now considerable interest in exploring the psychotherapeutic potential of hallucinogens, with 13 trials of psilocybin (2) undertaken in 2020 alone [5]. The renewed exploration of hallucinogens in a therapeutic setting raises important ethical and scientific consideration, and highlights the need for basic research on the action of hallucinogens in human brain [6,7]. The only recent review on imaging of hallucinogen actions focusses mainly on the fMRI literature [8]. Given this background, we now present a narrative review of the present state of the molecular imaging literature on hallucinogenic molecules. We emphasize first the selectivity and affinity of hallucinogenic compounds for serotonin receptors in vitro, discuss their fitness as radioligands for autoradiographic binding studies, and finally review the rather sparse literature on PET and SPECT studies with hallucinogens. Our aim is to extract general principles from the available results, and identify topics for future research in this domain. While various ancient peoples knew about plant- and animal-derived hallucinogens, the modern era of interest in hallucinogens began with the accidental discovery of the mind-altering effects of the ergot derivative LSD (1) (Figure 1). The extraordinary nature of experiences provoked by hallucinogens naturally motivated scientists to seek an understanding of their psychopharmacology and mechanisms of action. Hallucinogens belong to a variety of structural classes, including ergolines, phenylethylamines, and tryptamines (Figure 1, Figure 2, Figure 3 and Figure 5). As presented below, there is a general agreement that hallucinogens of the psychedelics class are agonists at serotonin 5HT2A receptors; although drugs of diverse other pharmacological classes can also induce hallucinations, we mainly confine this review to serotoninergic substances. However, the full spectrum of a given hallucinogen’s action may well entail actions at other serotonin receptors as well as receptors of dopamine, noradrenaline, histamine, trace amines, and neurotransmitter uptake sites (e.g., [9,10]). The spectrum of target engagement must somehow account for the overlapping and distinct aspects of the phenomenologies of different hallucinogenic drugs. Indeed, small structural modifications of certain molecules can decisively influence their hallucinogenic potency. For example, unlike N,N-diethyltryptamine (N,N-DET, 3), the corresponding diethyl compound, 6-fluoro-N,N-diethyltryptamine (4) is without hallucinogenic action in humans [11]. Similarly, 2-bromo-LSD (BOL-148, 5), despite its engagement with serotonin 5HT2A receptors, does not evoke hallucinations [12], except perhaps in rare cases [13]. Recent investigation of this phenomenon indicated that halogenation of N,N-DET (3) did not alter its affinity for serotonin 5HT2A receptors or various other receptor types, but disabled the intracellular response to agonism, i.e., stimulation of phosphotidyl inositol (PI) turnover [14], which may be a necessary property of effective hallucinogens. However, hallucinogenic activity is not a simple binary phenomenon, but encompasses a range of visual and sensory experiences. For example, mescaline (6) tends to evoke a characteristic visual experience of “geometricization” of three-dimensional objects, as is depicted in certain Amerindian art traditions. Visual hallucinations hint at a pharmacological action in the visual cortex [15], which is a theme amenable to analysis using a neural network approach [16]. It remains unclear how the particulars of mescaline (6) pharmacology might account for its greater propensity to evoke a specific type of visual experience. Despite the broadly overlapping serotonin receptor binding profiles of hallucinogenic tryptamines, interactions at other receptor types may contribute to their overall psychopharmacology or the particular phenomenology of hallucinogenic experiences [17]. Indeed, pretreatment of volunteers with the selective 5HT2A/C antagonist ketanserin (7), while largely abolishing the hallucinations elicited by psilocybin (2), did not attenuate binocular rivalry switching [18] or effects on attentional tracking performance [19]. Furthermore, a compilation of reports for a broad range of substances shows that interactions of serotonin, dopamine, glutamate, and opioid receptors all contribute to aspects of the subjective experience [20]. Other relevant factors for psychedelic action include the relationship between plasma kinetics of a drug, permeability for the blood–brain barrier, duration of target engagement in the central nervous system, and the intensity of psychedelic experience. Finally, the phenomena of “flashbacks” and hallucinogen-persisting perception disorder (HPPD) sometimes occurring in LSD (1) users [21] may call for reassessing the notion that visual hallucinations are only due to acute pharmacological activation of serotonin receptors [22]. The first phase of molecular imaging of hallucinogenic compounds employed in vitro binding techniques for assessing affinities and ex vivo methods for revealing the cerebral uptake and binding of radiopharmaceuticals in brain of living animals (e.g., [23]). Molecular imaging by positron emission tomography (PET) and single photon computer tomography (SPECT) have emerged in recent years as mature technologies for monitoring neuroreceptor availability in living brain, for measuring the extent of target engagement by psychoactive drugs [24,25], and to detect physiological responses of the brain to a pharmacological challenge. PET/SPECT methods are admirably suited for studying the cerebral uptake and binding of hallucinogens and for testing effects of psychoactive compounds on physiological markers such as the cerebral metabolic rate for glucose (CMRglc) or cerebral blood flow (CBF). However, this literature is rather sparse; indeed, some well-known hallucinogens remain entirely uninvestigated by molecular imaging techniques.
What the sources say
- Partly supportedcites [2] Petranker, 2020, Psychedelic Research and the Need for Transparency: Polishing Alice’s Looking Glass, Front. Psychol. sourceExperimental — accuracy not yet measured
The Brief History section says psychedelics were globally prohibited in 1971 and that prohibition suppressed psychedelic-research publication rates for decades. It also describes a twenty-first-century research resurgence. The paper does not specifically say that prohibition impeded understanding of both the phenomenology and physiology of hallucinogen action. (LLM, conf=0.85)
- Not checked yetcites [3] Doblin, 2019, The Past and Future of Psychedelic Science: An Introduction to This Issue, J. Psychoact. Drugs source
Checked before — its earlier verdict is held back until a new check runs.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the full spectrum of a given hallucinogen’s action may well entail actions at other serotonin receptors as well as receptors of dopamine, noradrenaline, histamine, trace amines, and neurotransmitter uptake sites (e.g., [9,10]).”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 1. Introduction Structurally diverse ergolines, phenylethylamines, and tryptamines known collectively as hallucinogens induce perceptual and affective changes, extending from sensory distortions (illusions) to sensing of non-existent objects (hallucinations), with varying degree of control over or insight into the altered state. The sites of hallucinogen binding and action in the central nervous system are amenable to study by molecular imaging with positron emission tomography (PET) or single photon emission computer tomography (SPECT), and can now be studied by functional magnetic resonance imaging (fMRI) of cerebral perfusion and connectivity [1]. A prohibition against hallucinogen research established in many countries the 1970s was until recently an impediment to progress in our understanding of the phenomenology and physiology of hallucinogen action [2,3]; PubMed hits for the search term “hallucinogen” peaked in 1974, troughed around 1990, and have sustained a high level since 2010. Analysis of the literature in the past decade shows a shift in emphasis from preclinical studies especially of lysergic acid diethylamide (LSD) (1) towards more clinical applications, especially involving psilocybin (2) [4]. Indeed, there is now considerable interest in exploring the psychotherapeutic potential of hallucinogens, with 13 trials of psilocybin (2) undertaken in 2020 alone [5]. The renewed exploration of hallucinogens in a therapeutic setting raises important ethical and scientific consideration, and highlights the need for basic research on the action of hallucinogens in human brain [6,7]. The only recent review on imaging of hallucinogen actions focusses mainly on the fMRI literature [8]. Given this background, we now present a narrative review of the present state of the molecular imaging literature on hallucinogenic molecules. We emphasize first the selectivity and affinity of hallucinogenic compounds for serotonin receptors in vitro, discuss their fitness as radioligands for autoradiographic binding studies, and finally review the rather sparse literature on PET and SPECT studies with hallucinogens. Our aim is to extract general principles from the available results, and identify topics for future research in this domain. While various ancient peoples knew about plant- and animal-derived hallucinogens, the modern era of interest in hallucinogens began with the accidental discovery of the mind-altering effects of the ergot derivative LSD (1) (Figure 1). The extraordinary nature of experiences provoked by hallucinogens naturally motivated scientists to seek an understanding of their psychopharmacology and mechanisms of action. Hallucinogens belong to a variety of structural classes, including ergolines, phenylethylamines, and tryptamines (Figure 1, Figure 2, Figure 3 and Figure 5). As presented below, there is a general agreement that hallucinogens of the psychedelics class are agonists at serotonin 5HT2A receptors; although drugs of diverse other pharmacological classes can also induce hallucinations, we mainly confine this review to serotoninergic substances. However, the full spectrum of a given hallucinogen’s action may well entail actions at other serotonin receptors as well as receptors of dopamine, noradrenaline, histamine, trace amines, and neurotransmitter uptake sites (e.g., [9,10]). The spectrum of target engagement must somehow account for the overlapping and distinct aspects of the phenomenologies of different hallucinogenic drugs. Indeed, small structural modifications of certain molecules can decisively influence their hallucinogenic potency. For example, unlike N,N-diethyltryptamine (N,N-DET, 3), the corresponding diethyl compound, 6-fluoro-N,N-diethyltryptamine (4) is without hallucinogenic action in humans [11]. Similarly, 2-bromo-LSD (BOL-148, 5), despite its engagement with serotonin 5HT2A receptors, does not evoke hallucinations [12], except perhaps in rare cases [13]. Recent investigation of this phenomenon indicated that halogenation of N,N-DET (3) did not alter its affinity for serotonin 5HT2A receptors or various other receptor types, but disabled the intracellular response to agonism, i.e., stimulation of phosphotidyl inositol (PI) turnover [14], which may be a necessary property of effective hallucinogens. However, hallucinogenic activity is not a simple binary phenomenon, but encompasses a range of visual and sensory experiences. For example, mescaline (6) tends to evoke a characteristic visual experience of “geometricization” of three-dimensional objects, as is depicted in certain Amerindian art traditions. Visual hallucinations hint at a pharmacological action in the visual cortex [15], which is a theme amenable to analysis using a neural network approach [16]. It remains unclear how the particulars of mescaline (6) pharmacology might account for its greater propensity to evoke a specific type of visual experience. Despite the broadly overlapping serotonin receptor binding profiles of hallucinogenic tryptamines, interactions at other receptor types may contribute to their overall psychopharmacology or the particular phenomenology of hallucinogenic experiences [17]. Indeed, pretreatment of volunteers with the selective 5HT2A/C antagonist ketanserin (7), while largely abolishing the hallucinations elicited by psilocybin (2), did not attenuate binocular rivalry switching [18] or effects on attentional tracking performance [19]. Furthermore, a compilation of reports for a broad range of substances shows that interactions of serotonin, dopamine, glutamate, and opioid receptors all contribute to aspects of the subjective experience [20]. Other relevant factors for psychedelic action include the relationship between plasma kinetics of a drug, permeability for the blood–brain barrier, duration of target engagement in the central nervous system, and the intensity of psychedelic experience. Finally, the phenomena of “flashbacks” and hallucinogen-persisting perception disorder (HPPD) sometimes occurring in LSD (1) users [21] may call for reassessing the notion that visual hallucinations are only due to acute pharmacological activation of serotonin receptors [22]. The first phase of molecular imaging of hallucinogenic compounds employed in vitro binding techniques for assessing affinities and ex vivo methods for revealing the cerebral uptake and binding of radiopharmaceuticals in brain of living animals (e.g., [23]). Molecular imaging by positron emission tomography (PET) and single photon computer tomography (SPECT) have emerged in recent years as mature technologies for monitoring neuroreceptor availability in living brain, for measuring the extent of target engagement by psychoactive drugs [24,25], and to detect physiological responses of the brain to a pharmacological challenge. PET/SPECT methods are admirably suited for studying the cerebral uptake and binding of hallucinogens and for testing effects of psychoactive compounds on physiological markers such as the cerebral metabolic rate for glucose (CMRglc) or cerebral blood flow (CBF). However, this literature is rather sparse; indeed, some well-known hallucinogens remain entirely uninvestigated by molecular imaging techniques.
What the sources say
- Not checked — no full text of the sourcecites [9] Rickli, 2016, Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens, Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. source
- Partly supportedcites [10] McKenna, 1989, Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin, J. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) links hallucinogen affinity for a serotonin-receptor subtype with human hallucinogenic doses, supporting a possible serotonin-receptor role. Our copy does not link hallucinogens’ broader effects to dopamine, noradrenaline, histamine or trace-amine receptors, or to neurotransmitter uptake sites. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, the mouse head-twitch response behavioral paradigm and rat trials of drug discrimination may serve better to predict hallucinogenic potency of drugs in humans [28].”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 2. Binding Sites of Hallucinogens In Vitro > 2.1. The Nature of Agonist-Receptor Interactions Agonism at serotonin receptors is an essential property of hallucinogens. Most serotonin receptors couple to intracellular second messenger systems by one or more guanine nucleotide binding proteins (G-proteins); the presence of guanosine triphosphate (GTP) or its metabolically stable analogues in the receptor binding assay disfavors the binding of agonist ligands, but has no effect on antagonist binding. Thus, the addition of GTP to a binding assay causes a substantial loss of affinity of an agonist ligand in vitro, manifesting in a shift to the right of a displacement curve against the bonding of a labelled antagonist ligand. In general, agonist binding stimulates GTP/GDP exchange, which results in activation of the enzyme adenylate cyclase in the case of the Gs-type G-protein, inhibition of adenylyl cyclase in the case of Gi/o, and stimulation of phospholipase C in the case of Gq/11, among many possible signal transduction pathways. For example, agonists of 5HT1A sites such as 8-hydroxy-DPAT have no intrinsic effect on cyclic AMP (cAMP) production in rat hippocampal neurons, but inhibit the stimulation of adenylyl cyclase provoked by other receptor types [26], thus suggesting receptor coupling to second messenger systems via Gi/o-type G-proteins. In another assay system, the increased retention of [35S]-guanosine-5-O-(3-thio)-triphosphate in membranes reveals agonist interactions. Indeed, that assay may serve as a forensic tool for operationally predicting the hallucinogenic properties of members of a series of tryptamine derivatives [27]. However, the mouse head-twitch response behavioral paradigm and rat trials of drug discrimination may serve better to predict hallucinogenic potency of drugs in humans [28]. While the preponderance of evidence indicates that 5HT2A agonism is a necessary property of hallucinogens, this is not sufficient, since certain 5-HT2A receptor agonists such as lisuride (21) and ergotamine (22) (Figure 2) do not evoke hallucinations (e.g., [29]). Explaining this phenomenon may call for arguments from non-classical pharmacology, whereby agonists can engage different signal transduction pathways through the same receptor. Serotonin 5HT2A receptors typically couple to the Gq/11-mediated signaling pathway, which activates phospholipase C (PLC) to stimulate the formation of inositol phosphates and diacylglycerol, leading to Ca2+ release from the endoplasmic reticulum [30]. Although some hallucinogens only weakly stimulate this pathway, hallucinogenic potency may correlate with the efficacy in activating PLC [31]. On the other hand, LSD (1) was more effective at activating the 5HT2A/2C-coupled phospholipase A2 (PLA2) pathway that mediates arachidonic acid release, whereas the non-hallucinogenic compound 3-trifluoromethylphenyl-piperazine preferentially activated the PLC-IP pathway [32]. Hallucinogenic effects at 5HT2A receptors may also entail activation of the pertussis toxin (PTX)-sensitive heterotrimeric Gi/o proteins [33]. As such, it may be the second messenger pathways rather than the particular receptor targets that mediate psychedelic action. Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34]; this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) noted above. Certainly, the 5HT2A/mGluR2 dimer adds an additional level of complexity to the mechanism of action of hallucinogens. In the special case of presynaptic autoreceptors, silencing of neuronal electrical activity upon drug application is a functional indicator of agonism. Early electrophysiological research showed that administration of LSD (1) at a low dose (5–10 µg/kg) provoked silencing of serotonin neurons in the rat dorsal raphé [35], presumably via activation of 5HT1A autoreceptors. Various other hallucinogenic compounds (psilocin (8), N,N-dimethyltryptamine [DMT (9)], and bufotenin (10)) inhibit serotonin neuron activity with a potency following the rank order of their potency as hallucinogens [36]. In electrophysiological studies, treatment with 5-HT1A receptor antagonist WAY-100,635 (500 μg/kg, i.v.) prevented the inhibitory effect of LSD (1) on the firing rate of dopaminergic ventral tegmental neurons in the rat brain [37]. In the same study, treatment with a blocker of the trace amine-associated receptor (TAAR) type 1 also interfered in the effects of LSD (1) on dopamine neuron activity. In vitro binding competition studies indicated that LSD (1) and other hallucinogens possess some affinity for TAAR1 [9].
What the sources say
- Supportedcites [28] Halberstadt, 2020, Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species, Neuropharmacology source
The Discussion states that mouse head-twitch responses and rat drug-discrimination results correlate strongly with reported human hallucinogen potencies, supporting their predictive validity. It specifically endorses using the head-twitch paradigm to predict potency in humans. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, a compilation of reports for a broad range of substances shows that interactions of serotonin, dopamine, glutamate, and opioid receptors all contribute to aspects of the subjective experience [20].”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 1. Introduction Structurally diverse ergolines, phenylethylamines, and tryptamines known collectively as hallucinogens induce perceptual and affective changes, extending from sensory distortions (illusions) to sensing of non-existent objects (hallucinations), with varying degree of control over or insight into the altered state. The sites of hallucinogen binding and action in the central nervous system are amenable to study by molecular imaging with positron emission tomography (PET) or single photon emission computer tomography (SPECT), and can now be studied by functional magnetic resonance imaging (fMRI) of cerebral perfusion and connectivity [1]. A prohibition against hallucinogen research established in many countries the 1970s was until recently an impediment to progress in our understanding of the phenomenology and physiology of hallucinogen action [2,3]; PubMed hits for the search term “hallucinogen” peaked in 1974, troughed around 1990, and have sustained a high level since 2010. Analysis of the literature in the past decade shows a shift in emphasis from preclinical studies especially of lysergic acid diethylamide (LSD) (1) towards more clinical applications, especially involving psilocybin (2) [4]. Indeed, there is now considerable interest in exploring the psychotherapeutic potential of hallucinogens, with 13 trials of psilocybin (2) undertaken in 2020 alone [5]. The renewed exploration of hallucinogens in a therapeutic setting raises important ethical and scientific consideration, and highlights the need for basic research on the action of hallucinogens in human brain [6,7]. The only recent review on imaging of hallucinogen actions focusses mainly on the fMRI literature [8]. Given this background, we now present a narrative review of the present state of the molecular imaging literature on hallucinogenic molecules. We emphasize first the selectivity and affinity of hallucinogenic compounds for serotonin receptors in vitro, discuss their fitness as radioligands for autoradiographic binding studies, and finally review the rather sparse literature on PET and SPECT studies with hallucinogens. Our aim is to extract general principles from the available results, and identify topics for future research in this domain. While various ancient peoples knew about plant- and animal-derived hallucinogens, the modern era of interest in hallucinogens began with the accidental discovery of the mind-altering effects of the ergot derivative LSD (1) (Figure 1). The extraordinary nature of experiences provoked by hallucinogens naturally motivated scientists to seek an understanding of their psychopharmacology and mechanisms of action. Hallucinogens belong to a variety of structural classes, including ergolines, phenylethylamines, and tryptamines (Figure 1, Figure 2, Figure 3 and Figure 5). As presented below, there is a general agreement that hallucinogens of the psychedelics class are agonists at serotonin 5HT2A receptors; although drugs of diverse other pharmacological classes can also induce hallucinations, we mainly confine this review to serotoninergic substances. However, the full spectrum of a given hallucinogen’s action may well entail actions at other serotonin receptors as well as receptors of dopamine, noradrenaline, histamine, trace amines, and neurotransmitter uptake sites (e.g., [9,10]). The spectrum of target engagement must somehow account for the overlapping and distinct aspects of the phenomenologies of different hallucinogenic drugs. Indeed, small structural modifications of certain molecules can decisively influence their hallucinogenic potency. For example, unlike N,N-diethyltryptamine (N,N-DET, 3), the corresponding diethyl compound, 6-fluoro-N,N-diethyltryptamine (4) is without hallucinogenic action in humans [11]. Similarly, 2-bromo-LSD (BOL-148, 5), despite its engagement with serotonin 5HT2A receptors, does not evoke hallucinations [12], except perhaps in rare cases [13]. Recent investigation of this phenomenon indicated that halogenation of N,N-DET (3) did not alter its affinity for serotonin 5HT2A receptors or various other receptor types, but disabled the intracellular response to agonism, i.e., stimulation of phosphotidyl inositol (PI) turnover [14], which may be a necessary property of effective hallucinogens. However, hallucinogenic activity is not a simple binary phenomenon, but encompasses a range of visual and sensory experiences. For example, mescaline (6) tends to evoke a characteristic visual experience of “geometricization” of three-dimensional objects, as is depicted in certain Amerindian art traditions. Visual hallucinations hint at a pharmacological action in the visual cortex [15], which is a theme amenable to analysis using a neural network approach [16]. It remains unclear how the particulars of mescaline (6) pharmacology might account for its greater propensity to evoke a specific type of visual experience. Despite the broadly overlapping serotonin receptor binding profiles of hallucinogenic tryptamines, interactions at other receptor types may contribute to their overall psychopharmacology or the particular phenomenology of hallucinogenic experiences [17]. Indeed, pretreatment of volunteers with the selective 5HT2A/C antagonist ketanserin (7), while largely abolishing the hallucinations elicited by psilocybin (2), did not attenuate binocular rivalry switching [18] or effects on attentional tracking performance [19]. Furthermore, a compilation of reports for a broad range of substances shows that interactions of serotonin, dopamine, glutamate, and opioid receptors all contribute to aspects of the subjective experience [20]. Other relevant factors for psychedelic action include the relationship between plasma kinetics of a drug, permeability for the blood–brain barrier, duration of target engagement in the central nervous system, and the intensity of psychedelic experience. Finally, the phenomena of “flashbacks” and hallucinogen-persisting perception disorder (HPPD) sometimes occurring in LSD (1) users [21] may call for reassessing the notion that visual hallucinations are only due to acute pharmacological activation of serotonin receptors [22]. The first phase of molecular imaging of hallucinogenic compounds employed in vitro binding techniques for assessing affinities and ex vivo methods for revealing the cerebral uptake and binding of radiopharmaceuticals in brain of living animals (e.g., [23]). Molecular imaging by positron emission tomography (PET) and single photon computer tomography (SPECT) have emerged in recent years as mature technologies for monitoring neuroreceptor availability in living brain, for measuring the extent of target engagement by psychoactive drugs [24,25], and to detect physiological responses of the brain to a pharmacological challenge. PET/SPECT methods are admirably suited for studying the cerebral uptake and binding of hallucinogens and for testing effects of psychoactive compounds on physiological markers such as the cerebral metabolic rate for glucose (CMRglc) or cerebral blood flow (CBF). However, this literature is rather sparse; indeed, some well-known hallucinogens remain entirely uninvestigated by molecular imaging techniques.
What the sources say
- Partly supportedcites [20] Zamberlan, 2018, The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines, Front. Integr. Neurosci. sourceExperimental — accuracy not yet measured
The Abstract and Results report that, across psychedelic phenethylamines and tryptamines, binding affinities involving serotonin, dopamine, glutamate, and opioid receptors helped predict similarities in reported subjective effects (page numbers unavailable). The paper calls this preliminary, correlational evidence; it does not establish that interactions at each receptor type causally contribute to experience across a broad range of substances. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34];”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 2. Binding Sites of Hallucinogens In Vitro > 2.1. The Nature of Agonist-Receptor Interactions Agonism at serotonin receptors is an essential property of hallucinogens. Most serotonin receptors couple to intracellular second messenger systems by one or more guanine nucleotide binding proteins (G-proteins); the presence of guanosine triphosphate (GTP) or its metabolically stable analogues in the receptor binding assay disfavors the binding of agonist ligands, but has no effect on antagonist binding. Thus, the addition of GTP to a binding assay causes a substantial loss of affinity of an agonist ligand in vitro, manifesting in a shift to the right of a displacement curve against the bonding of a labelled antagonist ligand. In general, agonist binding stimulates GTP/GDP exchange, which results in activation of the enzyme adenylate cyclase in the case of the Gs-type G-protein, inhibition of adenylyl cyclase in the case of Gi/o, and stimulation of phospholipase C in the case of Gq/11, among many possible signal transduction pathways. For example, agonists of 5HT1A sites such as 8-hydroxy-DPAT have no intrinsic effect on cyclic AMP (cAMP) production in rat hippocampal neurons, but inhibit the stimulation of adenylyl cyclase provoked by other receptor types [26], thus suggesting receptor coupling to second messenger systems via Gi/o-type G-proteins. In another assay system, the increased retention of [35S]-guanosine-5-O-(3-thio)-triphosphate in membranes reveals agonist interactions. Indeed, that assay may serve as a forensic tool for operationally predicting the hallucinogenic properties of members of a series of tryptamine derivatives [27]. However, the mouse head-twitch response behavioral paradigm and rat trials of drug discrimination may serve better to predict hallucinogenic potency of drugs in humans [28]. While the preponderance of evidence indicates that 5HT2A agonism is a necessary property of hallucinogens, this is not sufficient, since certain 5-HT2A receptor agonists such as lisuride (21) and ergotamine (22) (Figure 2) do not evoke hallucinations (e.g., [29]). Explaining this phenomenon may call for arguments from non-classical pharmacology, whereby agonists can engage different signal transduction pathways through the same receptor. Serotonin 5HT2A receptors typically couple to the Gq/11-mediated signaling pathway, which activates phospholipase C (PLC) to stimulate the formation of inositol phosphates and diacylglycerol, leading to Ca2+ release from the endoplasmic reticulum [30]. Although some hallucinogens only weakly stimulate this pathway, hallucinogenic potency may correlate with the efficacy in activating PLC [31]. On the other hand, LSD (1) was more effective at activating the 5HT2A/2C-coupled phospholipase A2 (PLA2) pathway that mediates arachidonic acid release, whereas the non-hallucinogenic compound 3-trifluoromethylphenyl-piperazine preferentially activated the PLC-IP pathway [32]. Hallucinogenic effects at 5HT2A receptors may also entail activation of the pertussis toxin (PTX)-sensitive heterotrimeric Gi/o proteins [33]. As such, it may be the second messenger pathways rather than the particular receptor targets that mediate psychedelic action. Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34]; this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) noted above. Certainly, the 5HT2A/mGluR2 dimer adds an additional level of complexity to the mechanism of action of hallucinogens. In the special case of presynaptic autoreceptors, silencing of neuronal electrical activity upon drug application is a functional indicator of agonism. Early electrophysiological research showed that administration of LSD (1) at a low dose (5–10 µg/kg) provoked silencing of serotonin neurons in the rat dorsal raphé [35], presumably via activation of 5HT1A autoreceptors. Various other hallucinogenic compounds (psilocin (8), N,N-dimethyltryptamine [DMT (9)], and bufotenin (10)) inhibit serotonin neuron activity with a potency following the rank order of their potency as hallucinogens [36]. In electrophysiological studies, treatment with 5-HT1A receptor antagonist WAY-100,635 (500 μg/kg, i.v.) prevented the inhibitory effect of LSD (1) on the firing rate of dopaminergic ventral tegmental neurons in the rat brain [37]. In the same study, treatment with a blocker of the trace amine-associated receptor (TAAR) type 1 also interfered in the effects of LSD (1) on dopamine neuron activity. In vitro binding competition studies indicated that LSD (1) and other hallucinogens possess some affinity for TAAR1 [9].
What the sources say
- Partly supportedcites [34] Ang, 2008, Identification of a serotonin/glutamate receptor complex implicated in psychosis, Nature sourceExperimental — accuracy not yet measured
The passages describing the binding experiments and functional assays report allosteric effects on serotonin-agonist binding and signaling by the 2AR/mGluR2 complex. The passage on molecular chimeras calls the heterodimer a predicted model and says larger oligomers are not excluded, so the definitive description of the complex as a heterodimer goes beyond what the paper establishes. The supplied passages are labeled Abstract and have no page numbers. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
129 more claims · 24 with their cited sources checked
Create a free account to see all 245 claims and to verify the 22 references still open.
- It may state two separate claims as one. 104
- Probably not a substantial claim. 11
- The quote only partly states this claim. 1
Citations
Cites
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Molecular biology of 5-HT receptors
Hannon, J., & Hoyer, D. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.03.020 · Cited by 815 · cited 1×
“Serotonin 5HT2A receptors typically couple to the Gq/11-mediated signaling pathway, which activates phospholipase C (PLC) to stimulate the formation of inositol phosphates and diacylglycerol, leading to Ca2+ release from the endoplasmic reticulum [30].”
BackgroundIdentification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803 · cited 1×
“Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34]; this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) not…”
BackgroundPsilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 2×
“However, a single dose of psilocybin (2) provoked in healthy individuals a long-lasting increase in scores for the personality traits of openness to experience and mindfulness, which correlated inversely with reductions in [11C]-Cimbi-36 (38) binding [106].”
BackgroundBerg, K. A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., & Clarke, W. P. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.94 · Cited by 510
A non-hallucinogenic psychedelic analogue with therapeutic potential
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., et al. (2021) · Nature · doi:10.1038/s41586-020-3008-z · Cited by 473 · cited 1×
“Tabernanthalog (20) and a series of other ibogaine (17) analogues lacking the isoquinuclidine retained the capacity to promote synaptic plasticity, while being much less cardiotoxic and teratogenic than ibogaine (17) itself [65].”
BackgroundSanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455 · cited 1×
“Other research has shown that LSD (1) acts as a full or partial agonist at a broad range of serotonin receptors, including 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT6 [39], and has relatively high affinity at dopamine D3 receptors in rat striatum cryostat sections [40].”
BackgroundVollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Lysergic acid diethylamide: Sensitive neuronal units in the midbrain raphe
Aghajanian, G. K., Foote, W. E., & Sheard, M. H. (1968) · Science · doi:10.1126/science.161.3842.706 · Cited by 404 · cited 1×
“silencing of serotonin neurons in the rat dorsal raphé [35], presumably via activation of 5HT1A autoreceptors.”
BackgroundReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379 · cited 6×
“Mescaline (6) binds with rather low affinity (Ki) as an agonist at 5HT1A sites (5 µM), 5HT2A/C (6 µM against [3H]-ketanserin), alpha2 (1.4 µM) and TAAR1 (3.3 µM) receptors [9,43].”
BackgroundInfluentialTiteler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343 · cited 2×
“6 nM at 5HT1B sites [41], thus confirming the considerable 5HT1-binding propensity of LSD (1).”
BackgroundMethodVollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305
What Geometric Visual Hallucinations Tell Us about the Visual Cortex
Bressloff, P. C., Cowan, J. D., Golubitsky, M., Thomas, P. J., & Wiener, M. C. (2002) · Neural Computation · doi:10.1162/089976602317250861 · Cited by 290 · cited 1×
“Visual hallucinations hint at a pharmacological action in the visual cortex [15], which is a theme amenable to analysis using a neural network approach [16].”
MethodHalberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278 · cited 1×
“However, the mouse head-twitch response behavioral paradigm and rat trials of drug discrimination may serve better to predict hallucinogenic potency of drugs in humans [28].”
BackgroundNeuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268 · cited 2×
“DMT (9) also showed an interaction with moderate affinity at sigma receptors [54].”
BackgroundHuman psychopharmacology of N,N-dimethyltryptamine
Strassman, R. J. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00081-2 · Cited by 261 · cited 1×
“On the other hand, pretreatment with the 5HT1A antagonist pindolol potentiated the hallucinogenic effect of intravenous DMT (9) in healthy volunteers, suggesting a breaking effect of 5HT1A receptors on 5HT2A-evoked hallucinations in humans [57].”
BackgroundIncreased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., & Barbanoj, M. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0358-7 · Cited by 241
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109836 · Cited by 224
Gouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219
Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020835 · Cited by 200
Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2020) · doi:10.20944/preprints202011.0742.v1 · Cited by 200
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., Thomas, C. D., Hetzel, S. J., Henriquez, K. M., Ribaudo, A. S., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0540-6 · Cited by 188
Enzymatic formation of psychotomimetic metabolites from normally occurring compounds
Axelrod, J. (1961) · Science · doi:10.1126/science.134.3475.343 · Cited by 184
Barker, S. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00536 · Cited by 177
Valle, M., Maqueda, A. E., Rabella, M., Rodríguez-Pujadas, A., Antonijoan, R. M., Romero, S., Alonso, J. F., Mañanas, M. À., Barker, S., Friedlander, P., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.012 · Cited by 173 · cited 1×
“Furthermore, pretreatment with ketanserin (40 mg) blocked the visual hallucinations and electroencephalographic effects otherwise evoked by DMT (9) in healthy volunteers [51].”
BackgroundMartinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A. (2018) · Brain Sciences · doi:10.3390/brainsci8030047 · Cited by 171 · cited 1×
“Finally, the phenomena of “flashbacks” and hallucinogen-persisting perception disorder (HPPD) sometimes occurring in LSD (1) users [21] may call for reassessing the notion that visual hallucinations are only due to acute pharmacological activation of serotonin receptors [22].”
BackgroundShen, H.-W., Jiang, X.-L., C. Winter, J., & Yu, A.-M. (2010) · Current Drug Metabolism · doi:10.2174/138920010794233495 · Cited by 170
Bennett, J. P., & Snyder, S. H. (1975) · Brain Research · doi:10.1016/0006-8993(75)90234-6 · Cited by 165
Dumuis, A., Sebben, M., & Bockaert, J. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13142-8 · Cited by 155 · cited 1×
“For example, agonists of 5HT1A sites such as 8-hydroxy-DPAT have no intrinsic effect on cyclic AMP (cAMP) production in rat hippocampal neurons, but inhibit the stimulation of adenylyl cyclase provoked by other receptor types [26], thus suggesting receptor coupling to second messenger systems via Gi/o-type G-proteins.”
BackgroundLeo, D., Mus, L., Espinoza, S., Hoener, M. C., Sotnikova, T. D., & Gainetdinov, R. R. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.007 · Cited by 154 · cited 1×
“Conceivably, increased signaling by tyramine or phenylethylamine at TAARs upon the treatment with an MAO inhibitor may have interfered via autoreceptor effects with the potentiation of dopamine release [102].”
BackgroundSamoylenko, V., Rahman, M. M., Tekwani, B. L., Tripathi, L. M., Wang, Y.-H., Khan, S. I., Khan, I. A., Miller, L. S., Joshi, V. C., & Muhammad, I. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.10.030 · Cited by 148
Agonist Properties of N,N-Dimethyltryptamine at Serotonin 5-HT2A and 5-HT2C Receptors
Smith, R. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00110-5 · Cited by 147 · cited 1×
“Prima facia, this seems unlikely since DMT (9) substituted for a 5HT2A agonist in a rat behavioral drug discrimination trial against the antagonist ketanserin (7) [50].”
BackgroundPsilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans
Carter, O. L., Hasler, F., Pettigrew, J. D., Wallis, G. M., Liu, G. B., & Vollenweider, F. X. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0930-9 · Cited by 146 · cited 1×
“Indeed, pretreatment of volunteers with the selective 5HT2A/C antagonist ketanserin (7), while largely abolishing the hallucinations elicited by psilocybin (2), did not attenuate binocular rivalry switching [18] or effects on attentional tracking performance [19].”
BackgroundPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
Dolder, P. C., Schmid, Y., Steuer, A. E., Kraemer, T., Rentsch, K. M., Hammann, F., & Liechti, M. E. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0513-9 · Cited by 133 · cited 2×
“The pharmacokinetics of oral LSD (1) (100 and 200 μg) in human subjects indicated a mean plasma half-life of 2–6 h and a persistently close relationship between the individual LSD (1) concentration in plasma and the magnitude of subjective response within subjects, with moderate counterclockwise hysteresis during the…”
BackgroundSadzot, B., Baraban, J. M., Glennon, R. A., Lyon, R. A., Leonhardt, S., Jan, C.-R., & Titeler, M. (1989) · Psychopharmacology · doi:10.1007/bf00441948 · Cited by 132 · cited 3×
“5-MeO-DMT (15) has similar affinity at 5HT2A receptors (Ki = 200 nM), under binding conditions where LSD (1) had a Ki of only 1 nM [47], and had >100-fold selectivity for 5HT1A/B/C receptors relative to 5HT2A receptors in vitro [56].”
BackgroundEffect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000339w · Cited by 131 · cited 2×
“The corresponding Ki values against [123I]-DOI indicated ten-fold higher affinity at 5HT2A sites [10,14], which is presumably indicative of the greater competition between an agonist drug at agonist-labelled receptors, as has been established for the case of dopamine D2/3 receptors [46].”
BackgroundEttrup, A., Hansen, M., Santini, M. A., Paine, J., Gillings, N., Palner, M., Lehel, S., Herth, M. M., Madsen, J., Kristensen, J., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1686-8 · Cited by 128
Self-citationMaisonneuve, I. M., Keller, R. W., & Glick, S. D. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90634-3 · Cited by 126 · cited 1×
“An anecdotal report that ibogaine (17) reduced opioid craving found support from rat studies showing an attenuation of the morphineinduced dopamine release in rat striatum [58].”
BackgroundGlick, S. D., Maisonneuve, I. M., Kitchen, B. A., & Fleck, M. W. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01284-0 · Cited by 122
Carter, O. L., Pettigrew, J. D., Hasler, F., Wallis, G. M., Liu, G. B., Hell, D., & Vollenweider, F. X. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300621 · Cited by 118 · cited 1×
“Indeed, pretreatment of volunteers with the selective 5HT2A/C antagonist ketanserin (7), while largely abolishing the hallucinations elicited by psilocybin (2), did not attenuate binocular rivalry switching [18] or effects on attentional tracking performance [19].”
BackgroundGlennon, R. A., Raghupathi, R., Bartyzel, P., Teitler, M., & Leonhardt, S. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00082a014 · Cited by 113 · cited 1×
“2,5-Dimethoxy-4-iodoamphetamine (DOI) is a prototypical phenylethylamine 5-HT2A/2C receptor agonist, although having some affinity for 5HT1A receptors, as does a wide range of its phenylalkylamine derivatives [79].”
BackgroundDe Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.022 · Cited by 110
Classical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain
Dean, J. G., Liu, T., Huff, S., Sheler, B., Barker, S. A., Strassman, R. J., Wang, M. M., & Borjigin, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-45812-w · Cited by 107
Karst, M., Halpern, J. H., Bernateck, M., & Passie, T. (2010) · Cephalalgia · doi:10.1177/0333102410363490 · Cited by 106 · cited 1×
“Similarly, 2-bromo-LSD (BOL-148, 5), despite its engagement with serotonin 5HT2A receptors, does not evoke hallucinations [12], except perhaps in rare cases [13].”
BackgroundA Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
Savalia, N. K., Shao, L.-X., & Kwan, A. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.008 · Cited by 104
McKenna, D., & Peroutka, S. (1989) · The Journal of Neuroscience · doi:10.1523/jneurosci.09-10-03482.1989 · Cited by 103 · cited 2×
“The corresponding Ki values against [123I]-DOI indicated ten-fold higher affinity at 5HT2A sites [10,14], which is presumably indicative of the greater competition between an agonist drug at agonist-labelled receptors, as has been established for the case of dopamine D2/3 receptors [46].”
BackgroundRasmussen, K., & Aghajanian, G. K. (1986) · Brain Research · doi:10.1016/0006-8993(86)91090-5 · Cited by 103
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Lewis, C. R., Preller, K. H., Kraehenmann, R., Michels, L., Staempfli, P., & Vollenweider, F. X. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.020 · Cited by 102
(1975) · PubMed · Cited by 101
Blough, B. E., Landavazo, A., Decker, A. M., Partilla, J. S., Baumann, M. H., & Rothman, R. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3557-7 · Cited by 101 · cited 3×
“Furthermore, the IC50 of DMT (9) and its derivatives at 5HT2A sites did not seem to correlate with visual hallucination intensity in humans [52].”
BackgroundResultOrsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00240 · Cited by 99
Wong, D. F., Lever, J. R., Hartig, P. R., Dannals, R. F., Villemagne, V., Hoffman, B. J., Wilson, A. A., Ravert, H. T., Links, J. M., Scheffel, U., et al. (1987) · Synapse · doi:10.1002/syn.890010502 · Cited by 94 · cited 1×
“One of the very first receptor PET molecular imaging studies employed N1-([11C]methyl)-2-bromo-LSD ([11C]-MBL, 33) as a non-hallucinogenic ligand for serotonin 5HT2A receptors [84].”
MethodNardai, S., László, M., Szabó, A., Alpár, A., Hanics, J., Zahola, P., Merkely, B., Frecska, E., & Nagy, Z. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113245 · Cited by 94 · cited 1×
“Indeed, the activity of DMT (9) at sigma-1 receptors mediates cytoprotective properties against hypoxic neuron injury in vitro, and in the reperfusion injury model in vivo [55].”
BackgroundGLICK, S. D., MAISONNEUVE, I. M., & SZUMLINSKI, K. K. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05211.x · Cited by 92 · cited 1×
“However, its metabolite noribogaine (18) possessed some affinity (Ki 2 μM) as a partial agonist for μ-opioid [59] and κ-opioid receptors [60], although much less so than the κ-opioid agonist hallucinogen Salvinorum A.”
BackgroundThe Past and Future of Psychedelic Science: An Introduction to This Issue
Doblin, R. E., Christiansen, M., Jerome, L., & Burge, B. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1606472 · Cited by 87 · cited 1×
“A prohibition against hallucinogen research established in many countries the 1970s was until recently an impediment to progress in our understanding of the phenomenology and physiology of hallucinogen action [2,3]; PubMed hits for the search term “hallucinogen” peaked in 1974, troughed around 1990, and have sustained…”
BackgroundMCKENNA, D. (1989) · Neuropsychopharmacology · doi:10.1016/0893-133x(89)90010-9 · Cited by 86
Sex differences and serotonergic mechanisms in the behavioural effects of psilocin
Tylš, F., Páleníček, T., Kadeřábek, L., Lipski, M., Kubešová, A., & Horáček, J. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000198 · Cited by 86
Dark Classics in Chemical Neuroscience: Mescaline
Cassels, B. K., & Sáez-Briones, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00215 · Cited by 85
Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y., & Taguchi, K. (2015) · Biological ^|^ Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00315 · Cited by 81 · cited 1×
“Rat microdialysis studies showed that psilocin (8) (10 mg/kg) evoked a transient 40% increase in interstitial dopamine levels [97], which would seem insufficient to account for the 20% displacement”
BackgroundMash, D. C., Staley, J. K., Pablo, J. P., Holohean, A. M., Hackman, J. C., & Davidoff, R. A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11608-y · Cited by 80 · cited 1×
“Ibogaine (17) also had some affinity for NMDA receptors, displacing [3H]MK801 from caudate membranes with an IC50 of 5 μM [61], which may account for its dissociative side effects.”
BackgroundBufotenine: Toward an understanding of possible psychoactive mechanisms
McBride, M. C. (2000) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2000.10400456 · Cited by 74
Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors
Deliganis, A. V., Pierce, P. A., & Peroutka, S. J. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90178-8 · Cited by 73 · cited 2×
“Other displacement studies against [3H]-ketanserin likewise showed μM Ki at 5HT2A/C sites and insensitivity to addition of GTP, suggesting an antagonist interaction [49].”
BackgroundThe fate of psilocin in the rat
Kalberer, F., Kreis, W., & Rutschmann, J. (1962) · Biochemical Pharmacology · doi:10.1016/0006-2952(62)90050-3 · Cited by 73
Finnema, S. J., Stepanov, V., Ettrup, A., Nakao, R., Amini, N., Svedberg, M., Lehmann, C., Hansen, M., Knudsen, G. M., & Halldin, C. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.035 · Cited by 72
Ettrup, A., Svarer, C., McMahon, B., da Cunha-Bang, S., Lehel, S., Møller, K., Dyssegaard, A., Ganz, M., Beliveau, V., Jørgensen, L. M., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.02.001 · Cited by 72
Berlowitz, I., Walt, H., Ghasarian, C., Mendive, F., & Martin-Soelch, C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1607956 · Cited by 72
Cumming, P., Wong, D. F., Gillings, N., Hilton, J., Scheffel, U., & Gjedde, A. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200205000-00011 · Cited by 71
Self-citationZamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, F., Erowid, E., & Tagliazucchi, E. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00054 · Cited by 71 · cited 1×
“Furthermore, a compilation of reports for a broad range of substances shows that interactions of serotonin, dopamine, glutamate, and opioid receptors all contribute to aspects of the subjective experience [20].”
BackgroundN,N -dimethyltryptamine and the pineal gland: Separating fact from myth
Nichols, D. E. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117736919 · Cited by 69
Psychedelic Research and the Need for Transparency: Polishing Alice’s Looking Glass
Petranker, R., Anderson, T., & Farb, N. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.01681 · Cited by 69
Glennon, R. A., Dukat, M., El-Bermawy, M., Law, H., De Los Angeles, J., Teitler, M., King, A., & Herrick-Davis, K. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00039a004 · Cited by 67 · cited 1×
“This discrepancy doubtless reflects the tenfold better competition of a series of indolylalkylamines such as 5-MeO-DMT (15) against [123I]-DOI (16)-labelled 5HT2A agonist sites as compared to [3H]-ketanserin-labelled 5HT2A antagonist sites [53].”
Result(2001) · The Alkaloids: Chemistry and Biology · doi:10.1016/s0099-9598(01)56006-x · Cited by 64
Gaps and peculiarities in 5-HT2 receptor studies.
(1990) · PubMed · Cited by 62
Páleníček, T., Balíková, M., Bubeníková-Valešová, V., & Horáček, J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-0926-5 · Cited by 61 · cited 1×
“), with slow washout from brain suggesting a three-hour half-life [78].”
BackgroundMolecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder
Cumming, P. D., Abi‐Dargham, A., & Gründer, G. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113004 · Cited by 60 · cited 1×
“Molecular imaging by positron emission tomography (PET) and single photon computer tomography (SPECT) have emerged in recent years as mature technologies for monitoring neuroreceptor availability in living brain, for measuring the extent of target engagement by psychoactive drugs [24,25], and to detect physiological r…”
BackgroundSelf-citationdos Santos, R. G., Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s300656 · Cited by 60 · cited 1×
“The renewed exploration of hallucinogens in a therapeutic setting raises important ethical and scientific consideration, and highlights the need for basic research on the action of hallucinogens in human brain [6,7].”
BackgroundChristian, S. T., Harrison, R., Quayle, E., Pagel, J., & Monti, J. (1977) · Biochemical Medicine · doi:10.1016/0006-2944(77)90088-6 · Cited by 58
Elmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., & Baumann, M. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.033 · Cited by 58 · cited 1×
“Relative to 2,5-dimethoxyphenethylamines (2C compounds) and DOI, the N-methoxybenzylated compounds had much higher affinity for 5-HT2A receptors labelled with the antagonist ligand [3H]-MDL100907 in vitro [83].”
BackgroundHow ecstasy and psilocybin are shaking up psychiatry
Tullis, P. (2021) · Nature · doi:10.1038/d41586-021-00187-9 · Cited by 58 · cited 1×
“Indeed, there is now considerable interest in exploring the psychotherapeutic potential of hallucinogens, with 13 trials of psilocybin (2) undertaken in 2020 alone [5].”
BackgroundHalberstadt, A. L., Nichols, D. E., & Geyer, M. A. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2616-6 · Cited by 57
Kamata, T., Katagi, M., Kamata, H. T., Miki, A., Shima, N., Zaitsu, K., Nishikawa, M., Tanaka, E., Honda, K., & Tsuchihashi, H. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005835 · Cited by 57
dos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986422 · Cited by 55
Metabolism of lysergic acid diethylamide (LSD): an update
Libânio Osório Marta, R. F. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1638931 · Cited by 54
Asjad, H. M. M., Kasture, A., El-Kasaby, A., Sackel, M., Hummel, T., Freissmuth, M., & Sucic, S. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.797092 · Cited by 53 · cited 1×
“Ibogaine (17) also had moderately high affinity (Ki 2 μM) at dopamine transporters [62], albeit by binding to their inward facing conformation, which may attenuate amphetamine-evoked dopamine release.”
BackgroundRepeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors
Scheffel, U., Lever, J. R., Stathis, M., & Ricaurte, G. A. (1992) · Neuropharmacology · doi:10.1016/0028-3908(92)90126-a · Cited by 52 · cited 1×
“Rat autoradiographic studies with [125I]-MIL (24) revealed that repeated doses with the non-hallucinogenic psychostimulant MDMA evoked a substantial down-regulation of 5HT2-like receptors [68], which may be a marker of the phenomenon of tolerance to certain hallucinogens.”
BackgroundGupta, S. P., Singh, P., & Bindal, M. C. (1983) · Chemical Reviews · doi:10.1021/cr00058a003 · Cited by 51
Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET
Ettrup, A., Palner, M., Gillings, N., Santini, M. A., Hansen, M., Kornum, B. R., Rasmussen, L. K., Någren, K., Madsen, J., Begtrup, M., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.074021 · Cited by 50 · cited 1×
“The phenylethylamine 5-HT2A receptor agonist 2-(4-iodo-2,5-dimethoxyphenyl)- N-(2[(11)C-OCH3]methoxybenzyl) ethanamine ([11C]-Cimbi-5, 34) was investigated as a potential PET tracer in rats ex vivo and in pigs in vivo [87].”
MethodSelf-citationIn Vivo Long-Term Kinetics of Radiolabeled N,N-Dimethyltryptamine and Tryptamine
Vitale, A. A., Pomilio, A. B., Cañellas, C. O., Vitale, M. G., Putz, E. M., & Ciprian-Ollivier, J. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.083246 · Cited by 48 · cited 1×
“A planar scintigraphy study examined the biodistribution of radioactivity in rabbits following intravenous injection of 2-[131I]iodo-DMT [95].”
BackgroundKelly, P. A. T., Davis, C. J., & Goodwin, G. M. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90044-9 · Cited by 46
Hallucinogen actions on human brain revealed
Lee, H.-M., & Roth, B. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121358109 · Cited by 46 · cited 1×
“Screening indicated a moderate affinity for psilocin (2) at 5HT2B sites [45], which may have some bearing on the propensity of psilocybin to cause cardiac valvulopathy.”
BackgroundBlood Flow and Cerebral Laterality in the Mescaline Model of Psychosis
Hermle, L., Gouzoulis-Mayfrank, E., & Spitzer, M. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979352 · Cited by 44
Jørgensen, L. M., Weikop, P., Villadsen, J., Visnapuu, T., Ettrup, A., Hansen, H. D., Baandrup, A. O., Andersen, F. L., Bjarkam, C. R., Thomsen, C., et al. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16629483 · Cited by 44 · cited 3×
“In a generalization of the competition PET model, reductions in the availability of binding sites for the serotonin 5HT2A antagonist [18F]-altanserin (39) are indicative of increased release of endogenous serotonin after challenge with dexfenfluramine [104], and/or target engagement by competing drugs.”
BackgroundResultInfluentialNielsen, L. M., Holm, N. B., Leth‐Petersen, S., Kristensen, J. L., Olsen, L., & Linnet, K. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2031 · Cited by 44 · cited 2×
“They undergo hydroxylation, O-demethylation, Ndealkylation, and dehydrogenation in vivo, mainly via CYP3A4 and CYP2D6 [82].”
BackgroundMetabolic Fate of Hallucinogenic NBOMes
Leth-Petersen, S., Gabel-Jensen, C., Gillings, N., Lehel, S., Hansen, H. D., Knudsen, G. M., & Kristensen, J. L. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00450 · Cited by 43
Cohen, I., & Vogel, W. H. (1972) · Biochemical Pharmacology · doi:10.1016/0006-2952(72)90119-0 · Cited by 42 · cited 1×
“DMT (9) obtained a brain:blood partition ratio of about 5:1 after intraperitoneal injection in the rat, but disappears rapidly from tissue and circulation due to metabolism [94].”
BackgroundDifferential phospholipase C activation by phenylalkylamine serotonin 5‐HT2Areceptor agonists
Parrish, J. C., Braden, M. R., Gundy, E., & Nichols, D. E. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03477.x · Cited by 41
Grome, J. J., & Harper, A. M. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb12933.x · Cited by 39
Nakada, M. T., Wieczorek, C. M., & Rainbow, T. C. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90128-9 · Cited by 38 · cited 1×
“More detailed autoradiographic examination of D-[125I]-LSD (25) binding in rat brain indicated a single population of binding sites (KD 170 pM) in cerebral cortex, where the Bmax was about 4 pmol/g wet weight [73].”
BackgroundSynthesis and Pharmacological Activity of Fluorinated Tryptamine Derivatives
Kalir, A., & Szara, S. (1963) · Journal of Medicinal Chemistry · doi:10.1021/jm00342a019 · Cited by 38 · cited 1×
“For example, unlike N,N-diethyltryptamine (N,N-DET, 3), the corresponding diethyl compound, 6-fluoro-N,N-diethyltryptamine (4) is without hallucinogenic action in humans [11].”
BackgroundBarsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.002 · Cited by 38
Pedersen, K., Simonsen, M., Østergaard, S. D., Lajord Munk, O., Rosa-Neto, P., Olsen, A. K., Jensen, S. B., Møller, A., & Cumming, P. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.11.038 · Cited by 37 · cited 1×
“Neither was the expected potentiation of amphetamine-evoked dopamine release seen in a [11C]raclopride PET study in rats with MAO inhibition [101].”
BackgroundSelf-citationDean, J. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00232 · Cited by 37
Halberstadt, A. L. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.01.005 · Cited by 35
Trends in the Top-Cited Articles on Classic Psychedelics
Lawrence, D. W., Sharma, B., Griffiths, R. R., & Carhart-Harris, R. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1874573 · Cited by 35 · cited 1×
“Analysis of the literature in the past decade shows a shift in emphasis from preclinical studies especially of lysergic acid diethylamide (LSD) (1) towards more clinical applications, especially involving psilocybin (2) [4].”
BackgroundMcKenna, D. J., Mathis, C. A., Shulgin, A. T., Sargent, T., & Saavedra, J. M. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90239-1 · Cited by 33 · cited 1×
“However, there was only sparse binding in striatum, consistent with the ligand’s considerable specificity for serotonin receptors [72].”
BackgroundMüller, F., Liechti, M. E., Lang, U. E., & Borgwardt, S. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.004 · Cited by 31 · cited 1×
“The sites of hallucinogen binding and action in the central nervous system are amenable to study by molecular imaging with positron emission tomography (PET) or single photon emission computer tomography (SPECT), and can now be studied by functional magnetic resonance imaging (fMRI) of cerebral perfusion and connectiv…”
BackgroundMcKenna, D. J., & Saavedra, J. M. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90121-x · Cited by 30 · cited 1×
“Autoradiographic studies with D-[125I]-LSD (25) (200 pM) showed abundant binding in the extended striatum and the cerebral cortex, and nearly complete displacement of the cortical binding be co-incubation with R-(-)-DOB ((-)12, 500 pM), but only 50% displacement in striatum, consistent with the ambivalence of LSD (1)…”
BackgroundIn Vitro Screening of Psychoactive Drugs by [35S]GTP.GAMMA.S Binding in Rat Brain Membranes
Nonaka, R., Nagai, F., Ogata, A., & Satoh, K. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.2328 · Cited by 30
Metabolism of 5-methoxy-N,N dimethyltryptamine-14C in the rat
Agurell, S., Holmstedt, B., & Lindgren, J. E. (1969) · Biochemical Pharmacology · doi:10.1016/0006-2952(69)90185-3 · Cited by 30
Jensen, A. A., Halberstadt, A. L., Märcher-Rørsted, E., Odland, A. U., Chatha, M., Speth, N., Liebscher, G., Hansen, M., Bräuner-Osborne, H., Palner, M., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113979 · Cited by 28
Self-citationJensen, S. B., Olsen, A. K., Pedersen, K., & Cumming, P. (2006) · Synapse · doi:10.1002/syn.20258 · Cited by 27 · cited 5×
“The amphetamine challenge evoked the expected 15% displacement of [11C]-raclopride in striatum of living pigs, but there was no potentiation of the amphetamine effect in pigs pretreated with pargyline at a dose sufficient to block completely the specific binding of [11C]-harmine (48) (Figure 5) to MAO-A [100].”
BackgroundInfluentialSelf-citationDISTRIBUTION AND METABOLISM OF MESCALINE-C IN THE CAT BRAIN
Neff, N. H., Rossi, G., Chase, G. D., et al. (1964) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26748-9 · Cited by 26 · cited 1×
“Mescaline (6) was the first hallucinogen synthesized in the laboratory, and perhaps for this reason found early application in autoradiographic studies [44].”
Interaction between LSD and dopamine D2/3 binding sites in pig brain
Minuzzi, L., Nomikos, G. G., Wade, M. R., Jensen, S. B., Olsen, A. K., & Cumming, P. (2005) · Synapse · doi:10.1002/syn.20141 · Cited by 26 · cited 2×
“PET studies with [15O]-water in anesthetized pig did not indicate any effects of LSD (1) treatment on cerebral perfusion [98].”
MethodSelf-citationAltar, C. A., Boyar, W. C., & Marien, M. R. (1986) · Brain Research · doi:10.1016/0006-8993(86)91465-4 · Cited by 26 · cited 1×
“However, other binding studies with [125I]-LSD (25) revealed a significant ketanserin (7) displaceable component in rat striatum sections, ranging from 30% in rostral parts to 74% in the caudal regions [74].”
BackgroundPatterns of exploration in rats distinguish lisuride from lysergic acid diethylamide
Adams, L. M., & Geyer, M. A. (1985) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(85)90022-x · Cited by 26
Johansen, A., Hansen, H. D., Svarer, C., Lehel, S., Leth-Petersen, S., Kristensen, J. L., Gillings, N., & Knudsen, G. M. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17746179 · Cited by 25
The Sigma-1 Receptor–A Therapeutic Target for the Treatment of ALS?
Mavlyutov, T. A., Baker, E. M., Losenegger, T. M., Kim, J. R., Torres, B., Epstein, M. L., & Ruoho, A. E. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-50174-1_17 · Cited by 24
Pottie, E., Kupriyanova, O. V., Brandt, A. L., Laprairie, R. B., Shevyrin, V. A., & Stove, C. P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00189 · Cited by 24 · cited 2×
“Various isomers of 25H-NBOMe in which the two methoxy-groups are in different positions (ortho, meta, and para) were compared with respect to their efficacy in activating signaling pathways, in conjunction with molecular docking studies at the 5HT2A receptor binding pocket [66].”
BackgroundResult(1975) · PubMed · Cited by 23
Use of Molecular Imaging in Clinical Drug Development: a Systematic Review
Son, H., Jang, K., Lee, H., Kim, S. E., Kang, K. W., & Lee, H. (2019) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-019-00593-y · Cited by 23 · cited 1×
“Molecular imaging by positron emission tomography (PET) and single photon computer tomography (SPECT) have emerged in recent years as mature technologies for monitoring neuroreceptor availability in living brain, for measuring the extent of target engagement by psychoactive drugs [24,25], and to detect physiological r…”
BackgroundNeural network models for DMT-induced visual hallucinations
Schartner, M. M., & Timmermann, C. (2020) · Neuroscience of Consciousness · doi:10.1093/nc/niaa024 · Cited by 19 · cited 1×
“Visual hallucinations hint at a pharmacological action in the visual cortex [15], which is a theme amenable to analysis using a neural network approach [16].”
MethodHoffman, B. J., Scheffel, U., Lever, J. R., Karpa, M. D., & Hartig, P. R. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb13135.x · Cited by 18 · cited 1×
“N-methyl-2-[125I]-iodo-lysergic acid diethylamide ([125I]-MIL, 24) was developed as a presumably non-hallucinogenic ligand for the molecular imaging of serotonin receptors, whereby N-methylation of [125I]-LSD (25) was intended to impart greater selectivity and sensitivity for 5HT2 receptors [23].”
BackgroundHopf, A., & Eckert, H. (1969) · Psychopharmacologia · doi:10.1007/bf02456045 · Cited by 17
Rabin, R. A., & Winter, J. C. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00690-5 · Cited by 17 · cited 1×
“Ibogaine (17) and its metabolite noribogaine (18) enhanced the Gi/o-mediated inhibition of adenylyl cyclase by morphine or serotonin, while having no intrinsic effect on basal or forskolin-stimulated adenylyl cyclase [63].”
BackgroundMaschauer, S., Haller, A., Riss, P. J., Kuwert, T., Prante, O., & Cumming, P. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13370 · Cited by 17
Self-citationMinuzzi, L., & Cumming, P. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.01.010 · Cited by 15 · cited 1×
“Other research has shown that LSD (1) acts as a full or partial agonist at a broad range of serotonin receptors, including 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT6 [39], and has relatively high affinity at dopamine D3 receptors in rat striatum cryostat sections [40].”
BackgroundSelf-citationZea-Ponce, Y., Kegeles, L. S., Guo, N., Raskin, L., Bakthavachalam, V., & Laruelle, M. (2002) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00306-2 · Cited by 14 · cited 1×
“Subsequent SPECT studies with 2,5-dimethoxy-4-[123I]-iodoamphetamine (R-[123I]-DOI; [1-(4_iodo-2,5-dimethoxyphenyl)-propane-2-amin]) of high specific activity showed high uptake in thalamus, cortex, and striatum, and lesser accumulation in the midbrain and cerebellum in baboon [86].”
BackgroundLever, J. R., Scheffel, U. A., Musachio, J. L., Stathis, M., & Wagner, H. N. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90189-i · Cited by 13
Shi, J., Landry, M., Carrasco, G. A., Battaglia, G., & Muma, N. A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.001 · Cited by 13
Jiang, X.-L., Shen, H.-W., & Yu, A.-M. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.01.008 · Cited by 13
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · doi:10.1101/2021.02.24.432725 · Cited by 11
Stenbæk, D. S., Kristiansen, S., Burmester, D., Madsen, M. K., Frokjaer, V. G., Knudsen, G. M., & Fisher, P. M. (2019) · Human Brain Mapping · doi:10.1002/hbm.24511 · Cited by 11
Johansen, A., Holm, S., Dall, B., Keller, S., Kristensen, J. L., Knudsen, G. M., & Hansen, H. D. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0527-4 · Cited by 10 · cited 1×
“[11C]-formaldehyde) or demethylation of the other methoxygroup, yielding a relatively hydrophobic radiometabolite [93].”
BackgroundHarms, A., Gündisch, D., Müller, C. E., & Kovar, K.-A. (2000) · SLAS Discovery · doi:10.1177/108705710000500410 · Cited by 8
Tfelt‐Hansen, P. C. (2010) · Cephalalgia · doi:10.1177/0333102410392069 · Cited by 7 · cited 1×
“Similarly, 2-bromo-LSD (BOL-148, 5), despite its engagement with serotonin 5HT2A receptors, does not evoke hallucinations [12], except perhaps in rare cases [13].”
BackgroundIn vivo PET Imaging of [11C]CIMBI-5, a 5-HT2AR Agonist Radiotracer in Nonhuman Primates
Prabhakaran, J., DeLorenzo, C., Zanderigo, F., Knudsen, G. M., Gilling, N., Pratap, M., Jorgensen, M. J., Daunais, J., Kaplan, J. R., Parsey, R. V., et al. (2019) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30329 · Cited by 7 · cited 1×
“Others conducted a comparative PET study of [11C]-Cimbi-5 (34) and the antagonist [11C]-MDL100907 (35) in living non-human primates, finding that the antagonist ligand had two or three-fold higher BPND than [11C]-Cimbi-5 (34) in most brain regions [88]; pretreatment with MDL100907 did not completely displace [11C]-Cim…”
BackgroundA quantitative method for the selective 5-HT2A agonist 25CN-NBOH in rat plasma and brain
Breusova, K., Ernstsen, K. G., Palner, M., Linnet, K., Kristensen, J. L., & Kretschmann, A. C. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114016 · Cited by 7
Self-citationKorr, H. (1976) · Psychopharmacologia · doi:10.1007/bf00421558 · Cited by 5
Response to Tfelt-Hansen P: Is BOL-148 hallucinogenic?
Karst, M., Halpern, J., Bernateck, M., & Passie, T. (2011) · Cephalalgia · doi:10.1177/0333102410392074 · Cited by 4
Autoradiographic studies on the distribution of 3H-2,3,4-trimethoxy-?-phenylethylamine in the mouse
Korr, H., & Seiler, N. (1976) · Psychopharmacologia · doi:10.1007/bf00421549 · Cited by 3 · cited 1×
“Similar studies in mice with the non-hallucinogenic isomer of mescaline, [3H]2,3,4-trimethoxy-β-phenylethylamine (4 mg) showed a more homogeneous pattern of binding [77], suggesting that mescaline (6) evokes hallucinations through specific receptors or binding sites.”
Result
Research works printed but not linked: 2
- Shulgin, A.T., and Shulgin, A. (1997). THIKAL, The Continuation, Transform Press.
- Hasler, 2009, Role of prefrontal serotonin-2A receptors in self experience during pilocybin-indiced altered states, Neuropsychobiology, 59, 60
Cited by
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 57
“For example, after administratio of mescaline (5–10 mg/kg), some subjects perceived time faster and others slower [85,90,92,94,95,99].”
BackgroundNeuroimaging in psychedelic drug development: past, present, and future
Wall, M. B., Harding, R., Zafar, R. R., Rabiner, E. A., Nutt, D. J., & Erritzøe, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02271-0 · Cited by 46
“The utility of radioli-gands such as [18F]setoperone, [18F]altanserine and [11C] MDL100907 was limited by the methodological issues inherent in the evaluation of agonist compounds using antagonist PET radioligands [31].”
Berlowitz, I., Egger, K., & Cumming, P. D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.886408 · Cited by 47
“…to potentiate central action of the hallucinogenic component N,N-dimethyltryptamine (DMT), which is a hallucinogenic serotonin 5-HT2A agonist otherwise subject to rapid deamination in the gut following oral administration (Cumming, 2021), as attested by a series of selfexperiments (Ott, 1999).”
BackgroundSelf-citationCastelhano, J., Lima, G., Teixeira, M., Soares, C., Pais, M. L., & Castelo-Branco, M. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739053 · Cited by 48
“Rigorous research (possibly integrating PET with fMRI (Cumming et al., 2021)) is needed, taking into account the best clinical practices.”
Background
Metadata
- Authors
- Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C.
- Affiliations
- Queensland University of Technology (AU)
- University of Zurich (CH)
- University of Southern Denmark (DK)
- Department of Psychology, University of Fribourg, CH-1700 Fribourg, Switzerland
- Corresponding author
- Cumming, Paul
- ORCID
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-04-22
- Volume
- 26
- Issue
- 9
- Pages
- 2451
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8122807
- OpenAlex
- W3153638782
- Cited by
- 43
- References
- 151
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 11 · 2023: 9 · 2022: 12 · 2021: 2
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- QUT ePrints (Queensland University of Technology) (submittedVersion, cc-by)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- ETH Zürich Research Collection (cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- hallucinogens, psychedelics, 5-HT2A receptor, 5-HT1A receptor, PET radiotracer, blood-brain barrier permeability, cerebral perfusion, brain glucose metabolism
- MeSH terms
- Clinical Studies as Topic, Animals, Carrier Proteins, Cerebrovascular Circulation, Drug Evaluation, Preclinical, Energy Metabolism, Hallucinogens, Humans, Image Processing, Computer-Assisted, Protein Binding, Molecular Structure, Biomarkers, Tomography, Emission-Computed, Single-Photon, Drug Monitoring, Positron-Emission Tomography, Molecular Imaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.